Search Results
Feb 24, 2026, 09:00 ET Class Action Filed Against Beyond Meat, Inc. (BYND) Seeking Recovery for Investors - Contact The Gross Law Firm
material, non-cash impairment charge; (ii) the foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the SEC; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: March 24, 2026 Shareholders
More news about: The Gross Law Firm
Feb 24, 2026, 09:00 ET Investors who lost money on Plug Power Inc.(PLUG) should contact The Gross Law Firm about pending Class Action - PLUG
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.DEADLINE: April 3, 2026 Shareholders
More news about: The Gross Law Firm
Feb 24, 2026, 09:00 ET Investors in Inovio Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO
device was deficient; (ii) accordingly, Inovio was unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's
More news about: The Gross Law Firm
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma liefert erste Patientendosis in Phase 1/2a der klinischen Studie von Radiopharm Theranostics mit 177Lu-BetaBart (RV-01)
Dienstleistungen in Kombination mit einer spezialisierten Infrastruktur für die Entwicklung von Radiopharmazeutika von den klinischen Studien der Phasen I bis III bis hin zur Vermarktung. AtomVie betreut derzeit internationale Kunden, die klinische Studien in über 28 Ländern weltweit durchführen. AtomVie baut derzeit
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma suministra la primera dosis en el estudio clínico de Radiopharm Theranostics
regulatorios, de calidad y logísticos, junto con una infraestructura especializada para el desarrollo de radiofármacos, desde estudios clínicos de fase I a III hasta su comercialización. Actualmente, AtomVie presta servicios a clientes internacionales que realizan estudios clínicos en más de 28 países. AtomVie
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma fournit la première dose à un patient dans le cadre de l'étude clinique de phase 1/2a de Radiopharm Theranostics sur le 177Lu-BetaBart (RV-01)
de qualité, ainsi qu'une infrastructure spécialisée pour le développement de produits radiopharmaceutiques, depuis les études cliniques (phases I à III) jusqu'aux marchés commerciaux. AtomVie sert actuellement des clients internationaux qui mènent des études cliniques dans plus de 28 pays à travers le
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET New National Initiative Awards $7.5 Million to Connect Gen Z with In-Demand Career Pathways
in isolation, leaving students to navigate fragmented education and workforce systems without clear guidance on their next steps," said John Garcia III, executive director of the Pathways Impact Fund. "We're pooling philanthropic resources into a fund that can invest in and scale the sort of evidence-based
More news about: Pathways Impact Fund
Feb 24, 2026, 09:00 ET Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
projects, and signed over 60 collaborations—among which 10 have completed IND filings, 8 are active clinical programs, and 3 have advanced to Phase III or pivotal/confirmatory clinical stages.This strategic shareholding restructuring not only optimizes Sanyou Biopharma's ownership structure but
More news about: Sanyou Bio
Feb 24, 2026, 09:00 ET Class Counsel announces proposed Settlement of Stockholder Class Action on Behalf of Former Holders of Covetrus, Inc. Securities
appointed as counsel for the Class, and whether Plaintiffs and Plaintiffs' Counsel have adequately represented the interests of the Class in the Action; (iii) determine whether the proposed Settlement on the terms and conditions provided for in the Stipulation is fair, reasonable, and adequate to the Class,
More news about: Labaton Keller Sucharow LLP
Feb 24, 2026, 08:34 ET Bitmine Immersion Technologies (BMNR) Umumkan Kepemilikan ETH Mencapai 4,423 Juta Token dan Total Kepemilikan Kripto Maupun Total Uang Tunai Sebesar $9,6 Miliar
Bitmine tetap didukung oleh kelompok penting beranggotakan investor institusi seperti Cathie Wood dari ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital, dan investor pribadi Thomas "Tom" Lee guna mendukung tujuan Bitmine untuk mengakuisisi 5% ETH
More news about: Bitmine Immersion Technologies, Inc.
Feb 24, 2026, 08:30 ET Republic of Paraguay - Announces Expiration of Cash Tender Offer for Existing Bonds
without notice, Paraguay expects to announce: (i) the Maximum Purchase Price for each series; (ii) the Tendered Aggregate Purchase Price, for each series (iii) the aggregate principal amount of Tenders of each series of the Existing Bonds that have been accepted; and (iv) any proration of Tenders of the Existing
More news about: Republic of Paraguay
Feb 24, 2026, 08:10 ET GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm
trial, which evaluated annual multi-cancer screening with GRAIL's Galleri test, revealing that "[t]he primary endpoint of statistically significant Stage III-IV reduction was not observed." On this news, the price of GRAIL stock fell significantly.ABOUT ROBBINS GELLER: Robbins Geller Rudman
More news about: Robbins Geller Rudman & Dowd LLP
Feb 24, 2026, 08:00 ET FASTER, LIGHTER, MORE PRECISE: THE NEW NIKKOR Z 70-200MM F/2.8 VR S II LENS IS ENGINEERED FOR THE PROFESSIONAL IN PURSUIT OF PERFECTION
situations.7. The Z9, Z8, Z7II, Z6III, Z6II, ZR, Z5II, Z5, Zf, and Z50II support this function (as of February 24, 2026). Update the camera firmware to the latest version.8. Based on CIPA 2024 Standard. Yaw/pitch/roll correction performance with the Z6III (Synchro VR enabled, telephoto end,
More news about: Nikon Inc.
Feb 24, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution
More news about: Citius Pharmaceuticals, Inc.
Feb 24, 2026, 08:00 ET Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
clinical trial for our ATR-04 program and the initiation of dosing and anticipated enrollment in the Phase 1/2 clinical trial for our ATR-04 program, and (iii) statements about our clinical and preclinical programs, including ATR-01, and corporate and clinical/preclinical strategies.Any forward-looking
More news about: Azitra, Inc.
Feb 24, 2026, 07:09 ET Einride has Divested its Design Organization
[email protected] Merger Corp. IIIEric RosenfeldChief SPAC OfficerLegato Merger Corp. III[email protected]
More news about: Einride
Feb 24, 2026, 07:07 ET Natural Grocers® Celebrates Colorado With Three-Day Event, Mar. 3-5, 2026
www.naturalgrocers.com/sweepstakes. Sponsor: Vitamin Cottage Natural Food Markets, Inc.[iii] Offer available only to {N}power members, for in store purchases at participating Colorado Natural Grocers stores, 3/3/2026 - 3/5/2026. Discount
More news about: Natural Grocers by Vitamin Cottage, Inc.
Feb 24, 2026, 07:02 ET Einride has Divested its Design Organization
[email protected] Merger Corp. IIIEric RosenfeldChief SPAC OfficerLegato Merger Corp. III[email protected]
More news about: Einride
Feb 24, 2026, 07:00 ET Recurrent Energy Completes Sale of 200 MWh Battery Storage Facility to Hunt Energy Network in Texas
and, with the purchase of Fort Duncan, now owns and operates 420 MW of battery storage facilities.Pat Wood III, Executive Chairman of Hunt Energy Network, said, "We are fully committed to dramatically growing our presence within ERCOT, and this acquisition
More news about: Canadian Solar Inc.
Feb 24, 2026, 07:00 ET Keurig Dr Pepper Reports Q4 and Full Year 2025 Results and Provides 2026 Outlook
including, but not limited to, (i) the inherent uncertainty of estimates, forecasts and projections, (ii) global economic uncertainty or economic downturns, (iii) tariffs or the imposition of new tariffs, trade wars, barriers or restrictions, or threats of such actions and related uncertainty, (iv) the risk that
More news about: Keurig Dr Pepper
Feb 24, 2026, 06:45 ET Life Time Reports Fourth Quarter and Full-Year 2025 Financial Results
three months and year ended December 31, 2024, respectively, (ii) gain on sales of land of $(5.0) million for the year ended December 31, 2024, and (iii) other immaterial transactions that are unusual or non-recurring in nature of $(0.1) million for the three months ended December 31, 2025.
More news about: Life Time Group Holdings, Inc.
Feb 24, 2026, 06:30 ET Xenia Hotels & Resorts Reports Fourth Quarter and Full Year 2025 Results
such outbreaks, weather and climate-related events, such as hurricanes, tornadoes, floods, wildfires, and droughts, and natural or man-made disasters; (iii) inflation and inflationary pressures which increases labor costs and other costs of providing services to guests and complying with hotel brand standards,
More news about: Xenia Hotels & Resorts, Inc.
Feb 24, 2026, 06:27 ET Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
divestiture or amortization of intangible assets, that some may consider important in evaluating our performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not exclude all unusual or non-recurring
More news about: Elanco Animal Health